Literature DB >> 31714953

The Anti-inflammatory Effects of Cotrimoxazole Prophylaxis for People Living With Human Immunodeficiency Virus in Sub-Saharan Africa.

Claire D Bourke1,2, Andrew J Prendergast1,2.   

Abstract

Entities:  

Keywords:  Africa; HIV; cotrimoxazole; immune activation; mortality

Mesh：

Substances：

Year:  2020        PMID： 31714953      PMCID： PMC7336553          DOI： 10.1093/infdis/jiz495

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  37 in total

1.  Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.

Authors:  Wei Jiang; Michael M Lederman; Peter Hunt; Scott F Sieg; Kathryn Haley; Benigno Rodriguez; Alan Landay; Jeffrey Martin; Elizabeth Sinclair; Ava I Asher; Steven G Deeks; Daniel C Douek; Jason M Brenchley
Journal:  J Infect Dis       Date:  2009-04-15       Impact factor: 5.226

2.  Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.

Authors:  Netanya G Sandler; Xinyan Zhang; Ronald J Bosch; Nicholas T Funderburg; Andrew I Choi; Janet K Robinson; Derek M Fine; Robert W Coombs; Jeffrey M Jacobson; Alan L Landay; Daniel C Douek; Randall Tressler; Sarah W Read; Cara C Wilson; Steven G Deeks; Michael M Lederman; Rajesh T Gandhi
Journal:  J Infect Dis       Date:  2014-05-26       Impact factor: 5.226

3.  Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.

Authors:  Nicholas T Funderburg; Ying Jiang; Sara M Debanne; Norma Storer; Danielle Labbato; Brian Clagett; Janet Robinson; Michael M Lederman; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2013-11-18       Impact factor: 9.079

4.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

5.  Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

6.  Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

Authors:  A S Walker; D Ford; C F Gilks; P Munderi; F Ssali; A Reid; E Katabira; H Grosskurth; P Mugyenyi; J Hakim; J H Darbyshire; D M Gibb; A G Babiker
Journal:  Lancet       Date:  2010-03-27       Impact factor: 79.321

7.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

8.  Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals.

Authors:  Charles Preston Neff; Owen Krueger; Kathy Xiong; Sabrina Arif; Nichole Nusbacher; Jennifer M Schneider; Annie W Cunningham; Abigail Armstrong; Sam Li; Martin D McCarter; Thomas B Campbell; Catherine A Lozupone; Brent E Palmer
Journal:  EBioMedicine       Date:  2018-03-26       Impact factor: 8.143

Review 9.  The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review.

Authors:  Matteo Vassallo; Patrick Mercié; Jacqueline Cottalorda; Michel Ticchioni; Pierre Dellamonica
Journal:  Virol J       Date:  2012-08-27       Impact factor: 4.099

10.  Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.

Authors:  Zacchaeus Anywaine; Jonathan Levin; Ronnie Kasirye; Joseph Kayiira Lutaakome; Andrew Abaasa; Andrew Nunn; Heiner Grosskurth; Paula Munderi
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.